Current Pharmaceutical Design - Volume 29, Issue 6, 2023

Cannabis sativa L. has been used as medicine for thousands of years. Since the early identification of tetrahydrocannabinol (THC) in 1960, pharmacological activities were attributed to a group of unique structures named cannabinoids. For decades, research and development were applied to determine different cannabinoids and their medicinal properties. Nowadays there is evidence that the therapeutic benefits of Read More

Myrtenol (C10H16O) is a volatile compound belonging to the terpenoid family of monocyclic monoterpenes. It is one of the essential oils constituents of several aromatic plants, including the genera Myrtus, Tanacetum, Artemisia, Hyssopus, and Rhodiola. The oxidation of α-pinene can produce it. Several reports demonstrated the pharmacological properties of myrtenol, including its antioxidant, antibacterial, antifungal, Read More

Carbon dots (CDs) have recently attracted attention as a new class of photoluminescent materials with promising optical, chemical, and electrical properties. They have been proposed for various applications, such as pharmaceutical sensing, biomarker detection, and cellular bioimaging, by virtue of their economical synthesis, cheap starting materials, water-solubility, excellent chemical stability, good biocompatibility, and lo Read More

In this review, the analysis of solid-solid phase transitions between crystalline polymorphs of organic molecules is discussed. Although active pharmaceutical ingredients (APIs) are the scope of the review, whether an organic molecule has a biological activity or not does not particularly define its interactions in the crystalline state. Therefore, other small organic molecules have been included in this analysis and in certain Read More

MicroRNA (miRNA) are small, single-stranded, non-coding RNA molecules containing 20 to 25 nucleotides, present in all body fluids; they can be used as biomarkers, but much more than this as a therapy to replace missing protein or to downregulate excess or aberrant synthesis; here we report possible insight to future studies, needed in this exciting field.

Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephritis, which is mainly characterized by excessive IgA deposition in the glomerular mesangial area. Although exploring the pathogenesis of IgAN and improving the treatment strategies continuously, the exact pathogenesis of IgAN remains unclear and the disease still leads to high mortality. Recently, emerging evidence has demonstrated that Read More

Background: PRMT5 is a major enzyme responsible for the post-translational symmetric demethylation of protein arginine residues, which has been validated as an effective therapeutic target for cancer. Thus, many nucleoside-based PRMT5 inhibitors have been reported in the past year. Objective: To discover a novel series of non-nucleoside PRMT5 inhibitors through a molecular docking-based virtual screening approach. Read More